)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Context Therapeutics (CNTX) investor relations material
Context Therapeutics Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary10 Nov, 2025
Strategic focus and pipeline overview
Focused on externally sourced T-cell engagers targeting Claudin-6, Mesothelin, and Nectin-4, with two programs in the clinic and one nearing clinical entry.
Claudin-6 and Mesothelin programs are in clinical trials; Nectin-4 will enter the clinic soon.
Emphasis on targets validated by ADCs and CAR-Ts, aiming to address ADC resistance and expand patient eligibility.
Commercial strategy leverages rapid development and expansion into broader patient populations.
Claudin-6 (CTIM-76) program insights
Claudin-6 is a tumor-restricted, non-oncogenic protein, making it an ideal T-cell engager target.
T-cell engagers offer dosing flexibility, cost efficiency, and broader patient reach compared to CAR-Ts.
Early clinical data show a deep partial response in a heavily pretreated ovarian cancer patient.
Safety profile is promising, with manageable cytokine release syndrome (CRS) and anticipated dose-proportional liver enzyme elevations.
Interim data update expected in Q2, with plans to move rapidly into phase I-B and explore less frequent dosing.
Mesothelin (CT-95) program insights
Mesothelin is present in 30% of cancers but has been challenging due to protein shedding and lung toxicity risks.
The antibody design targets the tumor-bound portion, minimizing off-tumor effects and overcoming shed-related dosing issues.
Enrollment focuses on pancreatic, ovarian, and mesothelioma, with pancreatic as the primary area.
Low diagnostic cutoff enables broad patient inclusion; initial clinical data expected by summer.
Progression to phase I-B anticipated by end of 2026, pending safety adjudication.
CTIM-76: How to expand patient population?
CT-95: How to avoid lung toxicity and shed antigen?
CT202: How does pH-dependent design mitigate tox?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Context Therapeutics earnings date
Q4 202520 Mar, 2026
Next Context Therapeutics earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage